Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) reported a minor adjustment to its share capital following an on-market repurchase on 30 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

Key transaction details • Date and venue: 30 April 2026, on the Hong Kong Stock Exchange • Shares repurchased: 258,400 H shares, representing 0.0058 % of the company’s issued shares (excluding treasury shares) immediately prior to the transaction • Price range: HKD 3.42 to HKD 3.52 per share • Volume-weighted average price: HKD 3.4641 per share • Total consideration: HKD 0.90 million

Post-transaction share capital • Issued shares (excluding treasury shares): reduced from 4.46877 billion to 4.46852 billion • Treasury shares: increased from 53.56 million to 53.82 million • Total issued shares (including treasury shares): unchanged at 4.52233 billion

Repurchase mandate utilisation • Mandate granted on 27 May 2025 authorised buybacks of up to 451.56 million shares. • Cumulative repurchases under the mandate have reached 47.17 million shares, equivalent to 10.45 % of the company’s issued shares on the mandate date. • In line with listing rules, Weigao Group is subject to a moratorium on new share issues or sales/transfers of treasury shares until 31 May 2026.

The company confirmed that the repurchase complied with all relevant Hong Kong Stock Exchange listing rules and regulatory requirements.